Lumosa Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Lumosa Therapeutics şirketinin toplam hissedar öz sermayesi NT$1.4B ve toplam borcu NT$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla NT$1.6B ve NT$203.7M dir.

Anahtar bilgiler

Borç/özkaynak oranı

NT$0

Borç

Faiz karşılama oranı	n/a
Nakit	NT$609.05m
Eşitlik	NT$1.39b
Toplam yükümlülükler	NT$203.70m
Toplam varlıklar	NT$1.60b

Son finansal sağlık güncellemeleri

We're Hopeful That Lumosa Therapeutics (GTSM:6535) Will Use Its Cash Wisely

Nov 24

Recent updates

Lumosa Therapeutics'(GTSM:6535) Share Price Is Down 47% Over The Past Five Years.

Mar 10

We're Hopeful That Lumosa Therapeutics (GTSM:6535) Will Use Its Cash Wisely

Nov 24

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 6535 'nin kısa vadeli varlıkları ( NT$807.8M ) kısa vadeli yükümlülüklerini ( NT$197.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: 6535 şirketinin kısa vadeli varlıkları ( NT$807.8M ) uzun vadeli yükümlülüklerini ( NT$6.4M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 6535 borçsuzdur.

Borcun Azaltılması: 6535 son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 6535 şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: 6535 serbest nakit akışı her yıl % 17.4 1.9 yıl yetecek nakit akışına sahip olacaktır.

Lumosa Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're Hopeful That Lumosa Therapeutics (GTSM:6535) Will Use Its Cash Wisely

Recent updates

Lumosa Therapeutics Co., Ltd. to Report Q3, 2024 Results on Nov 11, 2024

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Lumosa Therapeutics Co., Ltd. to Report Q2, 2024 Results on Aug 08, 2024

Lumosa Therapeutics Co., Ltd. Receives Approval to Initiate Phase 2, Multiple-Dose Study of Its LT3001, A Novel Treatment for Acute Ischemic Stroke, in UK

Now 18% overvalued after recent price rise

Now 22% overvalued after recent price rise

Less than half of directors are independent

Less than half of directors are independent

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Lumosa Therapeutics Co., Ltd. announced that it expects to receive TWD 50 million in funding

Lumosa Therapeutics Co., Ltd. Announces the Change of Chairperson

Lumosa Therapeutics Co., Ltd. to Report Q1, 2024 Results on May 14, 2024

Full year 2023 earnings released: NT$1.47 loss per share (vs NT$3.05 loss in FY 2022)

Lumosa Therapeutics Co., Ltd., Annual General Meeting, May 02, 2024

Lumosa Therapeutics and CHI Memorial Announce New Study for Acute Stroke

New minor risk - Share price stability

Lumosa Therapeutics Co., Ltd. Receives Approval to Initiate Phase 2, Multiple-Dose Study of Its LT3001

Second quarter 2023 earnings released: NT$0.92 loss per share (vs NT$1.20 loss in 2Q 2022)

Full year 2022 earnings released: NT$3.05 loss per share (vs NT$0.64 profit in FY 2021)

Less than half of directors are independent

Second quarter 2022 earnings released: NT$1.20 loss per share (vs NT$0.74 loss in 2Q 2021)

First quarter 2022 earnings released: NT$1.14 loss per share (vs NT$0.46 profit in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Lumosa Therapeutics Co., Ltd., Annual General Meeting, May 24, 2022

Lumosa Therapeutics Announces US FDA Clearance of IND Application for a Phase 2 Multi-Dose Study of LT3001 in Patients with Acute Ischemic Stroke

Lumosa Therapeutics Co., Ltd. Announces Lt3001 Granted Fast TrackDesignation for the Treatment of Acute Ischemic Stroke Toexpedite the Drug Registration Process with the US FDA

Lumosa Announces the Completion of the Phase 1Clinical Trial on the Pharmacokinetics of Multiple Dosesand the Drug-Drug Interaction for LT3001

Lumosa Receives an Notification from AMed Regarding the Receipt of an Import Permit from Thai Food and Drug Administration for Naldebain

Lumosa Therapeutics Co., Ltd. announced that it has received TWD 330 million in funding

Investor sentiment improved over the past week

Second quarter 2021 earnings released: NT$0.74 loss per share (vs NT$0.67 loss in 2Q 2020)

Lumosa Therapeutics Co., Ltd. Announces Positive Results from LT3001 Phase 2a Clinical Trial in Acute Ischemic Stroke

Lumosa Therapeutics Co., Ltd. Announces the Granting of the Formulation Patent for LT1001

Patent of Lumosa’s LT5001 Product Granted by Taiwan Intellectual Property Office

First quarter 2021 earnings released: EPS NT$0.46 (vs NT$0.95 loss in 1Q 2020)

Chief Internal Auditor has left the company

Full year 2020 earnings released: NT$2.67 loss per share (vs NT$2.05 loss in FY 2019)

Lumosa Therapeutics Co., Ltd. announced that it expects to receive TWD 99.992 million in funding from Far Glory Life Insurance Co., Ltd., Asset Management Arm

Lumosa Therapeutics Co., Ltd. Announces Resignation of Ya-Ting Hsu as Chief Internal Auditor, Effective March 31, 2021

Lumosa Therapeutics'(GTSM:6535) Share Price Is Down 47% Over The Past Five Years.

Lumosa Therapeutics Co., Ltd. Announces Approval by Korean Intellectual Property Office and European Patent Office for Lumosa's LT3001, A New Drug for Acute Ischemic Stroke

New 90-day low: NT$33.45

Lumosa Therapeutics Receives Market Approval of LT001 from Singapore's Health Science Agency

Lumosa Therapeutics Co., Ltd. to Commence A Multi-Dose,Drug-Drug-Interaction, Phase I Trial of LT3001 for AIS

Lumosa Announces Completion of Enrollment Inphase 2 Clinical Trial of Its LT3001 for Thetreatment of Acute Ischemic Stroke

Lumosa Therapeutics Co., Ltd. announced that it has received TWD 855.5 million in funding from Center Laboratories, Inc. and other investors

We're Hopeful That Lumosa Therapeutics (GTSM:6535) Will Use Its Cash Wisely

Third quarter 2020 earnings released: NT$0.40 loss per share

New 90-day low: NT$33.90

Lumosa and AMed Sign a Supplementary Licensing Agreement for the Licensing of Extended-Release Analgesic Injection in Southeast Asia

First half earnings released

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin